Ziad A Ali1, Ruth Rinze2, Gillian Douglas2, Yanhua Hu3, Qingzhong Xiao3, Wei Qi4, Eileen McNeill2, Christina Bursill2, Isaac George4, David R Greaves5, Qingbo Xu3, Keith M Channon2. 1. Center for Interventional Vascular Therapy, Division of Cardiology, New York Presbyterian Hospital and Columbia University, New York, NY; Cardiovascular Research Foundation, New York, NY; Department of Cardiovascular Medicine, John Radcliffe Hospital and University of Oxford, Oxford, United Kingdom. 2. Department of Cardiovascular Medicine, John Radcliffe Hospital and University of Oxford, Oxford, United Kingdom. 3. Cardiovascular Division, King's College Hospital, London, United Kingdom. 4. Center for Interventional Vascular Therapy, Division of Cardiology, New York Presbyterian Hospital and Columbia University, New York, NY. 5. Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Abstract
BACKGROUND: Endothelial cell (EC) survival and regeneration are important determinants of the response to vascular injury that leads to neointimal hyperplasia and accelerated atherosclerosis. Nitric oxide (NO) is a key regulator of EC and endothelial progenitor cell function, but the pathophysiological mechanisms that regulate endothelial NO synthase in endothelial regeneration remain unclear. METHODS AND RESULTS: Endothelium-targeted overexpression of GTP cyclohydrolase (GCH) I increased levels of the endothelial NO synthase cofactor, tetrahydrobiopterin, in an EC-specific manner and reduced neointimal hyperplasia in experimental vein grafts in GCH/apolipoprotein E-knockout mice. These effects were mediated through enhanced donor-derived survival and recipient-derived repopulation of GCH transgenic ECs, revealed by tracking studies in Tie2-LacZ/GCH-Tg/apolipoprotein E-knockout recipient mice or donor grafts, respectively. Endothelial GCH overexpression increased endothelial NO synthase coupling and enhanced the proliferative capacity of ECs and circulating endothelial progenitor cell numbers after vascular injury. CONCLUSIONS: These observations indicate that endothelial tetrahydrobiopterin availability modulates neointimal hyperplasia after vascular injury via accelerated EC repopulation and growth. Targeting tetrahydrobiopterin-dependent endothelial NO synthase regulation in the endothelium is a rational therapeutic target to enhance endothelial regeneration and reduce neointimal hyperplasia in vascular injury states.
BACKGROUND: Endothelial cell (EC) survival and regeneration are important determinants of the response to vascular injury that leads to neointimal hyperplasia and accelerated atherosclerosis. Nitric oxide (NO) is a key regulator of EC and endothelial progenitor cell function, but the pathophysiological mechanisms that regulate endothelial NO synthase in endothelial regeneration remain unclear. METHODS AND RESULTS: Endothelium-targeted overexpression of GTP cyclohydrolase (GCH) I increased levels of the endothelial NO synthase cofactor, tetrahydrobiopterin, in an EC-specific manner and reduced neointimal hyperplasia in experimental vein grafts in GCH/apolipoprotein E-knockout mice. These effects were mediated through enhanced donor-derived survival and recipient-derived repopulation of GCH transgenic ECs, revealed by tracking studies in Tie2-LacZ/GCH-Tg/apolipoprotein E-knockout recipient mice or donor grafts, respectively. Endothelial GCH overexpression increased endothelial NO synthase coupling and enhanced the proliferative capacity of ECs and circulating endothelial progenitor cell numbers after vascular injury. CONCLUSIONS: These observations indicate that endothelial tetrahydrobiopterin availability modulates neointimal hyperplasia after vascular injury via accelerated EC repopulation and growth. Targeting tetrahydrobiopterin-dependent endothelial NO synthase regulation in the endothelium is a rational therapeutic target to enhance endothelial regeneration and reduce neointimal hyperplasia in vascular injury states.
Authors: Jonathan M Hill; Gloria Zalos; Julian P J Halcox; William H Schenke; Myron A Waclawiw; Arshed A Quyyumi; Toren Finkel Journal: N Engl J Med Date: 2003-02-13 Impact factor: 91.245
Authors: Elisabeth Dernbach; Carmen Urbich; Ralf P Brandes; Wolf K Hofmann; Andreas M Zeiher; Stefanie Dimmeler Journal: Blood Date: 2004-05-25 Impact factor: 22.113
Authors: Lin Xie; M A Hassan Talukder; Jian Sun; Saradhadevi Varadharaj; Jay L Zweier Journal: J Mol Cell Cardiol Date: 2015-06-25 Impact factor: 5.000
Authors: C Sampath; R Kalpana; T Ansah; C Charlton; A Hale; K M Channon; S Srinivasan; P R Gangula Journal: Dig Dis Sci Date: 2019-06-11 Impact factor: 3.199
Authors: Rupert Oberhuber; Gregor Riede; Benno Cardini; David Bernhard; Barbara Messner; Katrin Watschinger; Christina Steger; Gerald Brandacher; Johann Pratschke; Georg Golderer; Ernst R Werner; Manuel Maglione Journal: Sci Rep Date: 2016-11-24 Impact factor: 4.379